TRISALUS LIFE SCIENCES

TriSalus Life Sciences® was created to develop and commercialize an innovative approach for the treatment of liver and pancreatic tumors. Our platform approach addresses immune dysfunction in liver and pancreatic tumors by combining immunotherapy drugs with highly effective drug delivery technology. Our company's heritage is in the development of devices for our Pressure-Enabled Drug Delivery™ (PEDD™) method. Building on this history, we launched our new platform in 2020 with the acquisition of SD-101. SD-101 is an investigational toll-like receptor 9 (TLR9) agonist with the potential to modulate the immune system to enable immunotherapy... Our team brings a powerful combination of proven clinical, strategic and commercial capabilities and a passion for developing solutions that positively impact the lives of patients... We believe that comprehensively addressing these two barriers has the potential to improve the lives of patients with liver and pancreatic tumors. Our therapeutic..

Also known as: TriSalus Life Sciences, Inc.

Primary location: Westminster United States